Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CLEC-2: the inside story. Blood 2015 Jun 25;125(26):3972-4

Date

06/27/2015

Pubmed ID

26113533

Pubmed Central ID

PMC4481588

DOI

10.1182/blood-2015-04-636233

Scopus ID

2-s2.0-84933567256 (requires institutional sign-in at Scopus site)   3 Citations

Abstract

In this issue of Blood, Lorenz et al elucidate the mechanisms by which antibody-mediated targeting of platelet C-type lectinlike receptor 2 (CLEC-2) induces receptor downregulation and thrombocytopenia. This information is important because antibody-mediated targeting of CLEC-2 may have therapeutic utility as antithrombotic therapy, especially if thrombocytopenia can be avoided.

Author List

Newman DK

Authors

Debra K. Newman PhD Investigator in the Blood Research Institute department at BloodCenter of Wisconsin
Debra K. Newman PhD Professor in the Pharmacology and Toxicology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Animals
Blood Platelets
Lectins, C-Type
Male
Platelet Activation